InvestorsHub Logo
Post# of 14595
Next 10
Followers 971
Posts 383001
Boards Moderated 6
Alias Born 06/24/2011

Re: None

Thursday, 09/21/2017 9:19:39 AM

Thursday, September 21, 2017 9:19:39 AM

Post# of 14595
$PSID DELRAY BEACH, Fla., Sept. 19, 2017 (GLOBE NEWSWIRE) -- One of the biggest barriers to delivering rapid diagnosis and care during a biological outbreak is about to be eliminated, said Lyle L. Probst, President, CEO and Founder of PositiveID Corporation’s (PSID) ExcitePCR subsidiary.

When asked what makes ExcitePCR’s FireflyDX™ technologies different than other pathogen detection solutions, Probst said, “Sample preparation takes place inside our FireflyDX systems, which means our customers can go from sample capture to answer in 30 minutes or less. On top of that, the FireflyDX devices are small, portable PCR-based units which can be used virtually anywhere around the world. These are just some of the things that set our pathogen detection systems apart from other solutions.” Internal Sample Preparation, Small Size and Rapid Results Differentiate the FireflyDX Systems, says Lyle Probst During BioWatch Panel
https://finance.yahoo.com/news/internal-sample-preparation-small-size-120000072.html

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.